Uveitis Market

Market Overview:

The uveitis market reached a value of USD 1,557.8 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 2,884.9 Million by ​2035​, exhibiting a growth rate (CAGR) of 5.78% during ​2025-2035​.

The uveitis market has been comprehensively analyzed in IMARC's new report titled "Uveitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ​2025-2035​". Uveitis refers to a type of eye inflammation. It affects the uvea, the middle layer of tissue in the eyewall. The illness can damage one or both eyes and affect people of all ages, including children. Uveitis warning signs can appear suddenly and worsen rapidly. They include eye redness, discomfort, and blurred vision. Individuals suffering from this condition might experience problems, such as floaters, which are spots in the eye that look like tiny rods or chains of transparent bubbles floating around in the field of vision. The disorder can also cause photophobia, headaches, watering of the eye, a small pupil or a distorted pupil shape, etc. Diagnosing uveitis commonly involves a comprehensive eye exam, blood tests, and imaging scans. The healthcare provider may also utilize tonometry to measure the pressure inside the eye and optical coherence tomography (OCT) to check for changes in the rear structures of the eye. Furthermore, fluorescein angiography or indocyanine green angiography may be recommended to confirm a diagnosis and rule out numerous other conditions causing the underlying symptoms.

The escalating cases of autoimmune disorders, in which the immune system attacks healthy cells in the uvea, damaging the retina, vitreous body, and optic nerve, are primarily driving the uveitis market. In addition to this, the inflating utilization of corticosteroids, such as prednisolone and prednisone, which act by altering the immune system's function and preventing it from releasing substances that induce inflammation, is also creating a positive outlook for the market. Moreover, the widespread adoption of biodegradable intravitreal implant on account of its numerous advantages, such as sustained release of anti-inflammatory medication directly into the eye, reduced inflammation, and improved visual acuity, is further bolstering the market growth. Apart from this, the rising usage of vitrectomy that involves removing or replacing the vitreous gel in the eye, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of nanoparticle-based formulation, since it can penetrate the eye's barriers more effectively, thereby allowing for targeted delivery of medications directly to the inflamed tissues within the eye and potentially reducing the frequency of injections, is expected to drive the uveitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the uveitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for uveitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the uveitis market in any manner.

Recent Developments:

• In September 2024, Priovant Therapeutics announced that the first patients had been enrolled in CLARITY, a Phase 3 study of brepocitinib in non-anterior, non-infectious uveitis. Brepocitinib additionally received Fast Track Designation for non-infectious uveitis by the FDA.
• In January 2024, Tarsier Pharma, Ltd. announced that it had received FDA approval under a Special Protocol Assessment (SPA) for the clinical trial protocol and planned statistical analysis of the Tarsier-04 Phase 3 trial to assess TRS01 eye drops for the treatment of non-infectious uveitis, including uveitic glaucoma.
• In January 2024, Celltrion USA reported the launch of an 80mg dose of YUFLYMA (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of HUMIRA (adalimumab) biosimilar in the U.S. These additional dose amounts, together with the two-step auto-injector option, allow greater flexibility and convenience for self-administration.

Drugs:

Hyrimoz (adalimumab-adaz) is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients. The method of action involves binding to TNF-α, a pro-inflammatory cytokine that plays a critical role in immune-mediated inflammation. Hyrimoz neutralizes TNF-α, reducing inflammation and protecting ocular tissues. This suppresses immune cell activation, cytokine release, and vascular permeability, so aiding in inflammation control, pain relief, and eyesight protection. Hyrimoz is particularly effective against non-infectious uveitis, preventing disease development and consequences such as vision loss and retinal damage.

Humira is a prescription medication used to treat non-infectious intermediate (middle portion of the eye), posterior (rear of the eye), and panuveitis (all parts of the eye) in adults and children aged 2 years and above. Humira's mode of action is to precisely target and block tumor necrosis factor-alpha, a crucial inflammatory protein in the immune system. This disrupts immune system signals that induce excessive inflammation.

Yuflyma (adalimumab-aaty) is a TNF-alpha inhibitor used to treat non-infectious intermediate, posterior, and panuveitis in adult patients. The drug inhibits TNF-alpha from interacting with its receptors, lowering inflammation and immune system overactivity. This causes a decrease in cytokine production, immune cell infiltration, and tissue damage in the eye. By lowering the inflammatory response, YUFLYMA relieves symptoms, prevents ocular damage, and preserves vision in patients with chronic or recurrent uveitis.

Brepocitinib, developed by Priovant Therapeutics, is a potential first-in-class dual selective inhibitor of tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) being studied for the treatment of uveitis. It works by inhibiting the activities of both TYK2 and JAK1, which are important signaling molecules in the inflammatory cascade that leads to uveitis. By blocking these pathways, it efficiently limits the production of pro-inflammatory cytokines like IL-12, IL-23, and IFN-γ. This reduces inflammation in the eye associated with uveitis.

Barcitinib, marketed by Eli Lilly and Company, works by inhibiting specific Janus kinase (JAK) enzymes, especially JAK1 and JAK2, hence disrupting the inflammatory signaling pathway by blocking STAT protein phosphorylation and activation. This reduces the generation of inflammatory cytokines that contribute to the development of uveitis. Essentially, Baricitinib suppresses the immune system by targeting important inflammatory mediators.

Time Period of the Study

• Base Year: 2024
• Historical Period: ​2019-2024​
• Market Forecast: ​2025-2035​

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the uveitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the uveitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current uveitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the uveitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the uveitis market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the uveitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of uveitis across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of uveitis by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of uveitis by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with uveitis across the seven major markets?
• What is the size of the uveitis patient pool (​2019-2024​) across the seven major markets?
• What would be the forecasted patient pool (​2025-2035​) across the seven major markets?
• What are the key factors driving the epidemiological trend of uveitis?
• What will be the growth rate of patients across the seven major markets?

Uveitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for uveitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the uveitis market?
• What are the key regulatory events related to the uveitis market?
• What is the structure of clinical trial landscape by status related to the uveitis market?
• What is the structure of clinical trial landscape by phase related to the uveitis market?
• What is the structure of clinical trial landscape by route of administration related to the uveitis market?